Task X21: Preparedness for Testing NIAID Priority Vaccines in General Safety and Toxicology Studies

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: RANDI  HORNBACK
Organization: BATTELLE CENTERS/PUB HLTH RES & EVALUATN
Fiscal Year: 2020
Award: $814,926
Funding agency: National Institute of Allergy and Infectious Diseases

The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through manufacture of Phase I/II material, including assay development; immunogenicity and efficacy testing; clinical and nonclinical sample testing; and safety and toxicity testing.  These services will facilitate the development and introduction of new vaccines and biologics against potential agents of bioterrorism, drug-resistant pathogens, and emerging and re-emerging infectious diseases.

Terms: <2019 novel coronavirus><2019-nCoV><Biological><Biological Terrorism><Bioterrorism><COVID-19><COVID19><Clinical><CoV emergence><Communicable Diseases><Contracting Opportunities><Contracts><Development><Emerging Communicable Diseases><Emerging Infectious Diseases><Feasibility Studies><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><NIAID><National Institute of Allergy and Infectious Disease><Phase><Preparedness><Readiness><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Safety><Sampling><Services><Severe acute respiratory syndrome coronavirus 2><Testing><Toxicity Testing><Toxicity Tests><Toxicology><Vaccines><Wuhan coronavirus><antibiotic resistant pathogen><assay development><corona virus disease 2019><coronavirus disease 2019><coronavirus emergence><developmental><drug resistant pathogen><efficacy testing><emergent CoV><emergent coronavirus><emerging CoV><emerging coronavirus><evaluation/testing><immunogenicity><nCoV><new CoV><new coronavirus><new vaccines><next generation vaccines><novel CoV><novel coronavirus><novel vaccines><product development><safety testing><testing services><therapeutic agent development><therapeutic development>